Avammune Therapeutics is another great example of the India-US biotech bridge. With operations in Philadelphia and Bengaluru, this team of serial biotech entrepreneurs is pioneering accessible cancer immunotherapies that could democratize treatment in emerging markets like India!
What is the news?
- Avammune Therapeutics raised $12 million (Rs 100 crore) in Series A funding co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I. Additional participation came from IvyCap Ventures and returning investor 1Crowd.
- Founded in 2020 by Arun Papaiah, Srinivasan Namala, and Aditya Kulkarni, the company develops small-molecule immunotherapies targeting innate immunity
Why is it interesting?
- Their lead compound AVA-NP-695 represents a breakthrough approach, a small molecule ENPP1 inhibitor that could be more accessible than traditional biologics in the $100B immuno-oncology market.
- With a 40+ member team across global operations and collaborations with UCSF, Oxford, and the University of Queensland, they’re building truly international innovation.
- Their focus on oral/accessible therapies directly addresses the limited access to expensive IO treatments in India and emerging markets, a massive unmet need!
Read more: Avammune Therapeutics raises $12 million to advance cancer therapies – Times of India